Call To Pool Research Resources into Large Trials to Generate Evidence On COVID-19 Treatments

Published on: 

Applied Clinical Trials

EMA’s Human Medicines Committee has published a statement urging the EU research community to prioritize large randomized controlled studies because they are most likely to generate the conclusive evidence needed to enable rapid development and approval of potential treatments of COVID-19. The statement promotes a harmonized approach to data collection for COVID-19 clinical trials across the EU.

For more information, click here.